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In this issue, Tachibana et al. report the generation of the first chimeras from a nonhuman primate,
the rhesus monkey. Unlike mice, rhesus chimeras fail to form when embryonic stem cells are
injected into blastocysts. Instead, chimera formation is achieved by aggregation of several four-cell
embryos.Pluripotency, or the ability of an unspe-
cialized cell to give rise to all cell types
of the body, is a property of early embry-
onic cells before they progress toward
increased lineage restriction. The inner
cell mass (ICM) of the blastocyst and the
epiblast of the postimplantation embryo
are comprised of pluripotent cells, both
in vivo and when isolated and cultured
in vitro. Various assays prove that human
embryonic stem cells (hESCs), the in vitro
isolates of the ICM, are pluripotent, as
they can give rise to representatives of
all three germ layers in vitro and in tera-
tomas. However, a more stringent assay
routinely used in mice, the production
of chimeras by blastocyst injection to
confirm that injected ESCs functionally
contribute to all cell types of the body,
cannot ethically be done in the human.
Mitalipov and colleagues (Tachibana
et al., 2012) have now used the rhesus
monkey to examine the question of
whether primate ESCs can contribute to
chimeras.
Tachibana et al. (2012) report that,
unlike in the mouse system, monkey
ESCs are unable to contribute to chime-
rism when injected into monkey host
blastocysts or into four-cell embryos
(Figure 1). To rule out technical problems,
the authors transfer whole ICM colonies
into monkey blastocysts. Again, no
chimeras formed, but remarkably, the
injected ICM produced entire offspring,
either as singletons or as one of mono-
chorionic nonidentical twins. The ability
to form offspring in this way has no prece-
dence in mice. Although this finding is
consistent with pluripotency of monkey
ICM, it is also possible that the injectedICM already consists of lineage-restricted
cell types and as a whole is capable of
implanting using extraembryonic support
from the host. Furthermore, this does
not provide evidence that the ICM of
the host blastocyst has the ability to func-
tionally integrate injected cells to form
a chimera. Instead, it took the aggregation
of multiple very early stage four-cell
embryos to show that embryonic chime-
rism in monkeys is possible at all.
As with all negative results, the
inability of monkey ESCs to contribute to
chimeras via blastocyst injection leaves
unanswered whether their developmental
potential, as this result suggests, is
indeed more limited than that of mouse
(m)ESCs, or if, with the right tweaking,
a positive result may emerge in the future.
In other words, could there be a barrier
to chimerism that is unrelated to the
potentiality of the injected cells? Perhaps
the host environment is not conducive
to chimera formation. Tachibana et al.
provide evidence that at the time of
ESC injections, the ICM in early monkey
blastocysts differs from that of the early
mouse blastocyst in that it has already
segregated a primitive endoderm layer
(future extraembryonic tissues) from
an underlying epiblast (future embryo
proper), a developmental event that
does not occur until the late blastocyst
stage in mice (Cockburn and Rossant,
2010). The relative positions of these two
lineages are likely maintained by differen-
tial cell adhesion properties of the two
cell populations and may be critical for
organized embryo development. Conse-
quently, cell mixing, a prerequisite for
chimera formation, may not be tolerated.Cell 14Interestingly, there is evidence that even
in the mouse, ESCs do not efficiently
contribute to late blastocysts (Ohta
et al., 2008), possibly because the late
blastocyst is no longer amenable to incor-
porating additional cells. The remarkable
ability of whole ICM isolates when trans-
planted to continue development inde-
pendently within the host blastocyst is
further consistent with the notion that
spatial information may already exist and
is retained irrespective of the presence
of other ICM cells.
Specific cell adhesion properties of the
injected cells may also pose a barrier
to cell mixing with host cells. Whereas
mESCs tolerate single cell dissociation,
hESCs do not, and recent evidence
suggests that this is due to differences in
signaling by E-cadherin, a cell adhesion
molecule (Xu et al., 2010). Interestingly,
Tachibana et al. report that dissociation
of monkey ICM, like dissociation of
hESCs, results in cell death. This apparent
dependence of primate pluripotent cells
on specific cell adhesion signaling may
underlie at least in part their inability to
mix with other cells and incorporate
into hosts. It would be interesting to test
whether small molecules that rescue
single cell-dissociated hESCs (Xu et al.,
2010) can overcome a potential barrier
to cell mixing and enable chimera forma-
tion of dissociated monkey ESCs or ICM
cells with monkey ICM.
The observation of relatively early
lineage segregation into a primitive endo-
derm layer and an epiblast in monkey
ICM also has implications for interpreting
the developmental potential of derived
ESCs. In fact, it is thought that primate8, January 20, 2012 ª2012 Elsevier Inc. 19
Figure 1. Mouse and Monkey ESCs Differ in Chimera-Forming Potential
In the mouse (left), pluripotent stem cell lines have been generated from blastomeres (B-ESC), the ICM of blastocysts (ICM-ESC), and the epiblast of post-
implantation pregastrulation embryos (EpiSC). All form teratomas (Chung et al., 2006; Cockburn and Rossant, 2010; Nichols and Smith, 2011). B-ESCs and ICM-
ESCs can contribute to chimeras when aggregated with eight-cell embryos or when injected into blastocysts. EpiSCs perform very poorly in the chimera assay
when injected into early blastocysts. Given that early blastocysts are known to be chimera competent, this suggests that EpiSCs are not fully pluripotent, but it is
also possible that host and injected cells are not developmentally compatible. It would be interesting to test whether EpiSCs can contribute to a late blastocyst as
the nascent epiblast layer of that stage may be more compatible with EpiSC. Under appropriate culture conditions, EpiSCs can be converted to chimera-
competent ICM-ESCs (Nichols and Smith, 2011). Dissociated ICM cells are capable of contributing to chimeras when injected into early blastocysts (Gardner,
1968).
In themonkey (right), cultured pluripotent stem cells have so far failed to contribute to chimeras. This is likely due to the developmentally advanced pluripotency of
the ESCs (Epi-like). Converting existing ESCs to a more naive ICM-like state or generating B-ESCs may create chimera-competent ESCs, although it remains
unclear whether the developmentally advanced early monkey blastocyst is chimera competent. Injected intact whole ICMs (dissociation causes cell death) fail to
mix with host ICM but can form independent offspring (top).
B, blastomere; Epi, epiblast (embryonic ectoderm); ICM, inner cell mass; PE, primitive endoderm (hypoblast); TE, trophectoderm; (H) although not done in
monkey, achieved in human; color shading indicates developmental fate/potency as indicated; darker shades represent more advanced developmental stages.
Stippling indicates culture adaptation with largely unknown effects on developmental potency. Dashed arrow indicates phenotypic conversion in culture.(monkey and human) ESCs are more
equivalent to mouse epiblast stem cells,
which are derived from postimplanta-
tion embryos and are developmentally
advanced relative to naive mESCs (ICM-
ESCs) (Nichols and Smith, 2011). This
is an important consideration because
mouse epiblast stem cells, although they
can give rise to teratomas and are thus
pluripotent, have only a very limited ability
to contribute to chimeras. It is thus plau-
sible that the pluripotency status, or
chimera-forming ability, of ESCs may
indeed be a reflection of the develop-
mental status of the ICM—immature in
mouse, more advanced in monkey—at
the time of their derivation. However, an20 Cell 148, January 20, 2012 ª2012 Elsevieranalysis of early embryo development in
humans suggests that segregation of
primitive endoderm and epiblast does
not occur until the late blastocyst stage
(Roode et al., 2011), whereas hESCs
derived from an apparently more imma-
ture ICM still behave like developmentally
advanced epiblast stem cells.
Interestingly, hESCs have been derived
from blastomeres of early cleavage stage
embryos (Ilic et al., 2009), that is, at
an earlier stage than the typical blasto-
cyst. Do blastomere-derived hESCs re-
present an earlier developmental stage
than ICM-derived hESCs, and if so, would
equivalent monkey blastomere-derived
ESCs contribute to chimeras? EvidenceInc.exists that hESCs can acquire a naive
state; hESCs derived from ICM under
low-oxygen conditions (Lengner et al.,
2010) exhibit a more mESC-like pheno-
type, suggesting that it might be worth
exploring whether blastomere-derived
monkey ESCs or monkey ESCs derived
from early blastocysts under low oxygen
acquire a more naive pluripotent state
and become chimera competent.
In summary, although other explana-
tions are possible, the inability of monkey
ESCs to contribute to chimeric offspring
is consistent with other evidence that
primate (monkey and human) ESCs
display a developmentally advanced
epiblast stem cell state, rather than naive
pluripotency. Whether this reflects the
developmental status of the ICM at the
time of ESC derivation or differential
signaling requirements for the mainte-
nance of pluripotency (Roode et al.,
2011) should be further explored. In the
meantime, extrapolation from mouse
pluripotent stem cell data to inform
primate stem cell biology is likely to be
inadequate. For this reason, it is important
to encourage human stem cell biologists
to avoid false expectations from other
species such as the mouse. However,
if primate pluripotent stem cells can be
returned to the naive state of pluripo-
tency, their unequivocal value may befurther enhanced, and mouse models
may become more informative for human
medicine.
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Sci. USA 107, 8129–8134.Understanding Metastasis in Pancreatic
Cancer: A Call for New Clinical Approaches
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Although metastasis is a major cause of morbidity and mortality in patients with pancreatic cancer,
the requisite events are currently unknown. In this issue ofCell, Haeno et al. and Rhim et al. propose
that metastasis occurs much earlier than previously anticipated, with clear implications for
improving patient care.Pancreatic cancer is the most lethal
common malignancy, despite standardi-
zation of surgical techniques and ad-
vances in systemic treatments. Most
pancreatic cancer patients present with
inoperable disease and rapidly succumb
from a devastating illness characterized
by tumor spread and vital organ dysfunc-
tion, intractable pain, galloping cachexia,
and coagulopathy. Surgical resection
offers the only hope for cure in the 20%
of patients who qualify, yet few survive
longer than 5 or 10 years, and the distin-
guishing features of this subgroup of
patients are unknown. Systemic chemo-
therapy provides temporary benefits inadvanced disease, whereas it prolongs
survivalmeasurably in the adjuvant setting
presumably by targeting microscopic
foci of local and distant disease. Recent
intriguing genomic analyses of pancreatic
tumors proposed that the initial primary
tumor proliferates for several years before
producing metastatic clones (Yachida
et al., 2010); however, patients with very
small or clinically undetectable primary
tumors still have a high risk of developing
metastases. Therefore, understanding
the mechanistic details and temporal
pattern of pancreatic cancer metastasis
is critical for designing effective interven-
tions, as explored in this issue of Cell intwo articles by Rhim et al. (2012) and
Haeno et al. (2012).
A traditional view of cancer metastasis
seeks to identify the ‘‘seed and soil’’
factors that may promote this process.
Along these lines, it is pertinent to
consider the genetic rap sheet of the
most common form of pancreatic cancer
(pancreatic ductal adenocarcinoma or
PDAC), as the four hallmark mutations of
PDAC (KRAS [>90%], p16INK4A [>90%],
TP53 [70%], and SMAD4 [55%]) have
all previously been implicated in themeta-
static process in human samples and
genetically engineered mouse models.
Indeed, oncogenic KRAS is known to8, January 20, 2012 ª2012 Elsevier Inc. 21
